SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.Robert J. Jones, Simon J. Crabb, Tony Elliott et al.|Journal of Clinical Oncology|2021Cited by 3
First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma (RCC): An international multi-center study.Talal El Zarif, Toni K. Choueiri, Karl Semaan et al.|Journal of Clinical Oncology|2024Cited by 0